Lung Diseases Cies Search Engine [selected websites]

Blog Archive

Apr 3, 2008

Poniard Pharmaceuticals : Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin

March 26, 2008 - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced an agreement with W. C. Heraeus GmbH for the commercial manufacture and supply of picoplatin active pharmaceutical ingredient (API). Poniard is investigating picoplatin, the Company's lead product candidate, in four clinical trials, including the ongoing pivotal Phase 3 trial in small cell lung cancer, and is developing picoplatin as a potential new platform product for the treatment of solid tumors... Poniard's Press Rlease -